Global Pseudorabies Virus Vaccine Market Growth 2026-2032
The global Pseudorabies Virus Vaccine market size is predicted to grow from US$ 165 million in 2025 to US$ 253 million in 2032; it is expected to grow at a CAGR of 6.3% from 2026 to 2032.
Pseudorabies Virus Vaccine is a veterinary biological product used to protect pigs against pseudorabies virus infection, mainly covering piglets, fattening pigs, replacement gilts, sows and boars. It helps reduce clinical disease, mortality, reproductive losses and virus shedding in swine herds. The product scope mainly includes live attenuated vaccines, inactivated vaccines, gene-deleted marker vaccines and combination vaccines containing pseudorabies virus antigens, with freeze-dried live vaccines and oil-emulsion inactivated vaccines as the main product forms. The most common and highest-volume strain platforms are Bartha-K61, HB98 and C strain. Upstream inputs mainly include production strains, cell substrates, culture media, adjuvants, stabilizers, freeze-drying protectants, inactivating agents, packaging materials and cold-chain packaging materials. Downstream customers mainly include large-scale swine farming groups, breeding farms, commercial pig farms, veterinary drug distributors and animal disease control bodies. On an ex-factory finished-vaccine basis, global designed capacity in 2025 is estimated at about 2.28 billion doses, actual sales volume at about 1.64 billion doses, and the average ex-factory ASP at around USD 0.10 per dose, with an industry gross margin of about 46%?61%. Differentiated products such as marker vaccines, variant-strain inactivated vaccines and combination vaccines generally carry higher prices and margins than conventional live vaccines.
The current market for Pseudorabies Virus Vaccine is already a mature commercial segment within swine vaccines, with stable baseline immunization demand but clear regional differences. China and selected intensive swine-producing regions in Asia remain the most active demand centers, as large-scale farms continue to focus on reproductive stability, piglet survival, fattening herd health and farm-level purification programs. In parts of Europe and North America, disease eradication and monitoring systems are more mature, so commercial vaccine demand is relatively stable and mainly supported by a limited number of multinational animal health companies. Overall, this is not a high-growth emerging market, but a stable market driven by routine vaccination, product upgrading and higher-quality disease-control needs. Looking ahead, competition will gradually shift from the supply of conventional vaccines to comprehensive prevention solutions that better fit the immunization programs of large-scale swine farms. Integrated producers are paying more attention to strain matching, duration of protection, batch-to-batch consistency, safety and compatibility with other swine vaccines. This will encourage manufacturers to keep upgrading live vaccines, inactivated vaccines, gene-deleted marker vaccines and combination vaccines. Companies with stable manufacturing processes, strong strain reserves, field validation capabilities and farm-level technical service teams will be better positioned to enter the supplier systems of large farming groups. Future product value will come more from purification support, variant-strain control and improved overall immunization efficiency than from low-price competition alone. The main growth drivers include the expansion of intensive pig farming, normalized disease prevention, the need to improve sow productivity and demand for regional herd purification. Once pseudorabies spreads within a farm, it can cause meaningful production losses in breeding sows, piglets and fattening pigs, so large-scale farms usually include it in their stable vaccination management systems. As producers raise their requirements for biosecurity, disease monitoring and production performance, the value of vaccine suppliers is no longer limited to the product itself. It also includes immunization program design, antibody monitoring support, purification-route advice and on-site technical services. Stricter regulation and higher quality requirements for veterinary biological products also favor suppliers with stronger technical capabilities and more complete quality systems. Key restraints include hog-cycle volatility, product homogenization, lower demand in some purified regions and the difficulty of proving clear product differentiation. When farm profitability is weak, small and medium-sized farms may reduce disease-prevention spending, affecting routine vaccine purchases. At the same time, many suppliers compete in mainstream strain platforms, creating pressure from channels and pricing. For new-generation marker vaccines, variant-strain inactivated vaccines and combination products, research, registration, field validation and scaled manufacturing all require long development cycles, so commercialization is not easy. The market is expected to become more concentrated around companies with broader product portfolios, stable manufacturing quality, strong access to integrated farming groups and solid technical service capabilities, while smaller suppliers without clear differentiation may face increasing competitive pressure.
LP Information, Inc. (LPI) ' newest research report, the ?Pseudorabies Virus Vaccine Industry Forecast? looks at past sales and reviews total world Pseudorabies Virus Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Pseudorabies Virus Vaccine sales for 2026 through 2032. With Pseudorabies Virus Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pseudorabies Virus Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Pseudorabies Virus Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Pseudorabies Virus Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Pseudorabies Virus Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pseudorabies Virus Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pseudorabies Virus Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Pseudorabies Virus Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Pseudorabies Virus Vaccine market?
What factors are driving Pseudorabies Virus Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Pseudorabies Virus Vaccine market opportunities vary by end market size?
How does Pseudorabies Virus Vaccine break out by Type, by Application?
Pseudorabies Virus Vaccine is a veterinary biological product used to protect pigs against pseudorabies virus infection, mainly covering piglets, fattening pigs, replacement gilts, sows and boars. It helps reduce clinical disease, mortality, reproductive losses and virus shedding in swine herds. The product scope mainly includes live attenuated vaccines, inactivated vaccines, gene-deleted marker vaccines and combination vaccines containing pseudorabies virus antigens, with freeze-dried live vaccines and oil-emulsion inactivated vaccines as the main product forms. The most common and highest-volume strain platforms are Bartha-K61, HB98 and C strain. Upstream inputs mainly include production strains, cell substrates, culture media, adjuvants, stabilizers, freeze-drying protectants, inactivating agents, packaging materials and cold-chain packaging materials. Downstream customers mainly include large-scale swine farming groups, breeding farms, commercial pig farms, veterinary drug distributors and animal disease control bodies. On an ex-factory finished-vaccine basis, global designed capacity in 2025 is estimated at about 2.28 billion doses, actual sales volume at about 1.64 billion doses, and the average ex-factory ASP at around USD 0.10 per dose, with an industry gross margin of about 46%?61%. Differentiated products such as marker vaccines, variant-strain inactivated vaccines and combination vaccines generally carry higher prices and margins than conventional live vaccines.
The current market for Pseudorabies Virus Vaccine is already a mature commercial segment within swine vaccines, with stable baseline immunization demand but clear regional differences. China and selected intensive swine-producing regions in Asia remain the most active demand centers, as large-scale farms continue to focus on reproductive stability, piglet survival, fattening herd health and farm-level purification programs. In parts of Europe and North America, disease eradication and monitoring systems are more mature, so commercial vaccine demand is relatively stable and mainly supported by a limited number of multinational animal health companies. Overall, this is not a high-growth emerging market, but a stable market driven by routine vaccination, product upgrading and higher-quality disease-control needs. Looking ahead, competition will gradually shift from the supply of conventional vaccines to comprehensive prevention solutions that better fit the immunization programs of large-scale swine farms. Integrated producers are paying more attention to strain matching, duration of protection, batch-to-batch consistency, safety and compatibility with other swine vaccines. This will encourage manufacturers to keep upgrading live vaccines, inactivated vaccines, gene-deleted marker vaccines and combination vaccines. Companies with stable manufacturing processes, strong strain reserves, field validation capabilities and farm-level technical service teams will be better positioned to enter the supplier systems of large farming groups. Future product value will come more from purification support, variant-strain control and improved overall immunization efficiency than from low-price competition alone. The main growth drivers include the expansion of intensive pig farming, normalized disease prevention, the need to improve sow productivity and demand for regional herd purification. Once pseudorabies spreads within a farm, it can cause meaningful production losses in breeding sows, piglets and fattening pigs, so large-scale farms usually include it in their stable vaccination management systems. As producers raise their requirements for biosecurity, disease monitoring and production performance, the value of vaccine suppliers is no longer limited to the product itself. It also includes immunization program design, antibody monitoring support, purification-route advice and on-site technical services. Stricter regulation and higher quality requirements for veterinary biological products also favor suppliers with stronger technical capabilities and more complete quality systems. Key restraints include hog-cycle volatility, product homogenization, lower demand in some purified regions and the difficulty of proving clear product differentiation. When farm profitability is weak, small and medium-sized farms may reduce disease-prevention spending, affecting routine vaccine purchases. At the same time, many suppliers compete in mainstream strain platforms, creating pressure from channels and pricing. For new-generation marker vaccines, variant-strain inactivated vaccines and combination products, research, registration, field validation and scaled manufacturing all require long development cycles, so commercialization is not easy. The market is expected to become more concentrated around companies with broader product portfolios, stable manufacturing quality, strong access to integrated farming groups and solid technical service capabilities, while smaller suppliers without clear differentiation may face increasing competitive pressure.
LP Information, Inc. (LPI) ' newest research report, the ?Pseudorabies Virus Vaccine Industry Forecast? looks at past sales and reviews total world Pseudorabies Virus Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Pseudorabies Virus Vaccine sales for 2026 through 2032. With Pseudorabies Virus Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pseudorabies Virus Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Pseudorabies Virus Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Pseudorabies Virus Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Pseudorabies Virus Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pseudorabies Virus Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pseudorabies Virus Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Pseudorabies Virus Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Live Attenuated Vaccine
- Inactivated Vaccine
- Others
- Bartha-K61 Strain
- HB98 Strain
- C Strain
- Other
- Small Pack (Below 20 Doses per Vial)
- Medium Pack (20?50 Doses per Vial)
- Large Pack (Above 50 Doses per Vial)
- Large-scale Swine Farming Groups
- Breeding Farms
- Animal Disease Control Institutions
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- MSD Animal Health
- Boehringer Ingelheim
- HIPRA
- Ceva Sant? Animale
- Wuhan Keqian Biology
- Pulike Biological Engineering
- China Animal Husbandry Industry
- Jinyu Bio-Technology
- Guangdong Winsun Bio-Pharmaceutical
- Huapai Biopharm
- Jilin Zhengye Biological Products
- Sinopharm Yangzhou VAC Biological Engineering
- Sinovet Animal Health
- Jofunhwa Group
- Harbin Weike Biotechnology
- Qilu Animal Health Products
- Harbin Pharmaceutical Group Bio-vaccine
- Qingdao Yebio Bioengineering
What is the 10-year outlook for the global Pseudorabies Virus Vaccine market?
What factors are driving Pseudorabies Virus Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Pseudorabies Virus Vaccine market opportunities vary by end market size?
How does Pseudorabies Virus Vaccine break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Pseudorabies Virus Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Pseudorabies Virus Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Pseudorabies Virus Vaccine by Country/Region, 2021, 2025 & 2032
2.2 Pseudorabies Virus Vaccine Segment by Type
2.2.1 Live Attenuated Vaccine
2.2.2 Inactivated Vaccine
2.2.3 Others
2.2.4 Pseudorabies Virus Vaccine Sales by Type
2.2.4.1 Global Pseudorabies Virus Vaccine Sales Market Share by Type (2021-2026)
2.2.4.2 Global Pseudorabies Virus Vaccine Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Pseudorabies Virus Vaccine Sale Price by Type (2021-2026)
2.3 Pseudorabies Virus Vaccine Segment by Strain Platform
2.3.1 Bartha-K61 Strain
2.3.2 HB98 Strain
2.3.3 C Strain
2.3.4 Other
2.3.5 Pseudorabies Virus Vaccine Sales by Strain Platform
2.3.5.1 Global Pseudorabies Virus Vaccine Sales Market Share by Strain Platform (2021-2026)
2.3.5.2 Global Pseudorabies Virus Vaccine Revenue and Market Share by Strain Platform (2021-2026)
2.3.5.3 Global Pseudorabies Virus Vaccine Sale Price by Strain Platform (2021-2026)
2.4 Pseudorabies Virus Vaccine Segment by Dose Pack Size
2.4.1 Small Pack (Below 20 Doses per Vial)
2.4.2 Medium Pack (20?50 Doses per Vial)
2.4.3 Large Pack (Above 50 Doses per Vial)
2.4.4 Pseudorabies Virus Vaccine Sales by Dose Pack Size
2.4.4.1 Global Pseudorabies Virus Vaccine Sales Market Share by Dose Pack Size (2021-2026)
2.4.4.2 Global Pseudorabies Virus Vaccine Revenue and Market Share by Dose Pack Size (2021-2026)
2.4.4.3 Global Pseudorabies Virus Vaccine Sale Price by Dose Pack Size (2021-2026)
2.5 Pseudorabies Virus Vaccine Segment by Application
2.5.1 Large-scale Swine Farming Groups
2.5.2 Breeding Farms
2.5.3 Animal Disease Control Institutions
2.5.4 Others
2.5.5 Pseudorabies Virus Vaccine Sales by Application
2.5.5.1 Global Pseudorabies Virus Vaccine Sale Market Share by Application (2021-2026)
2.5.5.2 Global Pseudorabies Virus Vaccine Revenue and Market Share by Application (2021-2026)
2.5.5.3 Global Pseudorabies Virus Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Pseudorabies Virus Vaccine Breakdown Data by Company
3.1.1 Global Pseudorabies Virus Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global Pseudorabies Virus Vaccine Sales Market Share by Company (2021-2026)
3.2 Global Pseudorabies Virus Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global Pseudorabies Virus Vaccine Revenue by Company (2021-2026)
3.2.2 Global Pseudorabies Virus Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global Pseudorabies Virus Vaccine Sale Price by Company
3.4 Key Manufacturers Pseudorabies Virus Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Pseudorabies Virus Vaccine Product Location Distribution
3.4.2 Players Pseudorabies Virus Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PSEUDORABIES VIRUS VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Pseudorabies Virus Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global Pseudorabies Virus Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Pseudorabies Virus Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Pseudorabies Virus Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global Pseudorabies Virus Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Pseudorabies Virus Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Pseudorabies Virus Vaccine Sales Growth
4.4 APAC Pseudorabies Virus Vaccine Sales Growth
4.5 Europe Pseudorabies Virus Vaccine Sales Growth
4.6 Middle East & Africa Pseudorabies Virus Vaccine Sales Growth
5 AMERICAS
5.1 Americas Pseudorabies Virus Vaccine Sales by Country
5.1.1 Americas Pseudorabies Virus Vaccine Sales by Country (2021-2026)
5.1.2 Americas Pseudorabies Virus Vaccine Revenue by Country (2021-2026)
5.2 Americas Pseudorabies Virus Vaccine Sales by Type (2021-2026)
5.3 Americas Pseudorabies Virus Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Pseudorabies Virus Vaccine Sales by Region
6.1.1 APAC Pseudorabies Virus Vaccine Sales by Region (2021-2026)
6.1.2 APAC Pseudorabies Virus Vaccine Revenue by Region (2021-2026)
6.2 APAC Pseudorabies Virus Vaccine Sales by Type (2021-2026)
6.3 APAC Pseudorabies Virus Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Pseudorabies Virus Vaccine by Country
7.1.1 Europe Pseudorabies Virus Vaccine Sales by Country (2021-2026)
7.1.2 Europe Pseudorabies Virus Vaccine Revenue by Country (2021-2026)
7.2 Europe Pseudorabies Virus Vaccine Sales by Type (2021-2026)
7.3 Europe Pseudorabies Virus Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Pseudorabies Virus Vaccine by Country
8.1.1 Middle East & Africa Pseudorabies Virus Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Pseudorabies Virus Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa Pseudorabies Virus Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa Pseudorabies Virus Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Pseudorabies Virus Vaccine
10.3 Manufacturing Process Analysis of Pseudorabies Virus Vaccine
10.4 Industry Chain Structure of Pseudorabies Virus Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Pseudorabies Virus Vaccine Distributors
11.3 Pseudorabies Virus Vaccine Customer
12 WORLD FORECAST REVIEW FOR PSEUDORABIES VIRUS VACCINE BY GEOGRAPHIC REGION
12.1 Global Pseudorabies Virus Vaccine Market Size Forecast by Region
12.1.1 Global Pseudorabies Virus Vaccine Forecast by Region (2027-2032)
12.1.2 Global Pseudorabies Virus Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Pseudorabies Virus Vaccine Forecast by Type (2027-2032)
12.7 Global Pseudorabies Virus Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 MSD Animal Health
13.1.1 MSD Animal Health Company Information
13.1.2 MSD Animal Health Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.1.3 MSD Animal Health Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 MSD Animal Health Main Business Overview
13.1.5 MSD Animal Health Latest Developments
13.2 Boehringer Ingelheim
13.2.1 Boehringer Ingelheim Company Information
13.2.2 Boehringer Ingelheim Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.2.3 Boehringer Ingelheim Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Boehringer Ingelheim Main Business Overview
13.2.5 Boehringer Ingelheim Latest Developments
13.3 HIPRA
13.3.1 HIPRA Company Information
13.3.2 HIPRA Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.3.3 HIPRA Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 HIPRA Main Business Overview
13.3.5 HIPRA Latest Developments
13.4 Ceva Sant? Animale
13.4.1 Ceva Sant? Animale Company Information
13.4.2 Ceva Sant? Animale Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.4.3 Ceva Sant? Animale Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Ceva Sant? Animale Main Business Overview
13.4.5 Ceva Sant? Animale Latest Developments
13.5 Wuhan Keqian Biology
13.5.1 Wuhan Keqian Biology Company Information
13.5.2 Wuhan Keqian Biology Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.5.3 Wuhan Keqian Biology Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Wuhan Keqian Biology Main Business Overview
13.5.5 Wuhan Keqian Biology Latest Developments
13.6 Pulike Biological Engineering
13.6.1 Pulike Biological Engineering Company Information
13.6.2 Pulike Biological Engineering Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.6.3 Pulike Biological Engineering Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Pulike Biological Engineering Main Business Overview
13.6.5 Pulike Biological Engineering Latest Developments
13.7 China Animal Husbandry Industry
13.7.1 China Animal Husbandry Industry Company Information
13.7.2 China Animal Husbandry Industry Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.7.3 China Animal Husbandry Industry Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 China Animal Husbandry Industry Main Business Overview
13.7.5 China Animal Husbandry Industry Latest Developments
13.8 Jinyu Bio-Technology
13.8.1 Jinyu Bio-Technology Company Information
13.8.2 Jinyu Bio-Technology Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.8.3 Jinyu Bio-Technology Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Jinyu Bio-Technology Main Business Overview
13.8.5 Jinyu Bio-Technology Latest Developments
13.9 Guangdong Winsun Bio-Pharmaceutical
13.9.1 Guangdong Winsun Bio-Pharmaceutical Company Information
13.9.2 Guangdong Winsun Bio-Pharmaceutical Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.9.3 Guangdong Winsun Bio-Pharmaceutical Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Guangdong Winsun Bio-Pharmaceutical Main Business Overview
13.9.5 Guangdong Winsun Bio-Pharmaceutical Latest Developments
13.10 Huapai Biopharm
13.10.1 Huapai Biopharm Company Information
13.10.2 Huapai Biopharm Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.10.3 Huapai Biopharm Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Huapai Biopharm Main Business Overview
13.10.5 Huapai Biopharm Latest Developments
13.11 Jilin Zhengye Biological Products
13.11.1 Jilin Zhengye Biological Products Company Information
13.11.2 Jilin Zhengye Biological Products Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.11.3 Jilin Zhengye Biological Products Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Jilin Zhengye Biological Products Main Business Overview
13.11.5 Jilin Zhengye Biological Products Latest Developments
13.12 Sinopharm Yangzhou VAC Biological Engineering
13.12.1 Sinopharm Yangzhou VAC Biological Engineering Company Information
13.12.2 Sinopharm Yangzhou VAC Biological Engineering Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.12.3 Sinopharm Yangzhou VAC Biological Engineering Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Sinopharm Yangzhou VAC Biological Engineering Main Business Overview
13.12.5 Sinopharm Yangzhou VAC Biological Engineering Latest Developments
13.13 Sinovet Animal Health
13.13.1 Sinovet Animal Health Company Information
13.13.2 Sinovet Animal Health Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.13.3 Sinovet Animal Health Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Sinovet Animal Health Main Business Overview
13.13.5 Sinovet Animal Health Latest Developments
13.14 Jofunhwa Group
13.14.1 Jofunhwa Group Company Information
13.14.2 Jofunhwa Group Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.14.3 Jofunhwa Group Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Jofunhwa Group Main Business Overview
13.14.5 Jofunhwa Group Latest Developments
13.15 Harbin Weike Biotechnology
13.15.1 Harbin Weike Biotechnology Company Information
13.15.2 Harbin Weike Biotechnology Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.15.3 Harbin Weike Biotechnology Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Harbin Weike Biotechnology Main Business Overview
13.15.5 Harbin Weike Biotechnology Latest Developments
13.16 Qilu Animal Health Products
13.16.1 Qilu Animal Health Products Company Information
13.16.2 Qilu Animal Health Products Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.16.3 Qilu Animal Health Products Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Qilu Animal Health Products Main Business Overview
13.16.5 Qilu Animal Health Products Latest Developments
13.17 Harbin Pharmaceutical Group Bio-vaccine
13.17.1 Harbin Pharmaceutical Group Bio-vaccine Company Information
13.17.2 Harbin Pharmaceutical Group Bio-vaccine Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.17.3 Harbin Pharmaceutical Group Bio-vaccine Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Harbin Pharmaceutical Group Bio-vaccine Main Business Overview
13.17.5 Harbin Pharmaceutical Group Bio-vaccine Latest Developments
13.18 Qingdao Yebio Bioengineering
13.18.1 Qingdao Yebio Bioengineering Company Information
13.18.2 Qingdao Yebio Bioengineering Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.18.3 Qingdao Yebio Bioengineering Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Qingdao Yebio Bioengineering Main Business Overview
13.18.5 Qingdao Yebio Bioengineering Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Pseudorabies Virus Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Pseudorabies Virus Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Pseudorabies Virus Vaccine by Country/Region, 2021, 2025 & 2032
2.2 Pseudorabies Virus Vaccine Segment by Type
2.2.1 Live Attenuated Vaccine
2.2.2 Inactivated Vaccine
2.2.3 Others
2.2.4 Pseudorabies Virus Vaccine Sales by Type
2.2.4.1 Global Pseudorabies Virus Vaccine Sales Market Share by Type (2021-2026)
2.2.4.2 Global Pseudorabies Virus Vaccine Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Pseudorabies Virus Vaccine Sale Price by Type (2021-2026)
2.3 Pseudorabies Virus Vaccine Segment by Strain Platform
2.3.1 Bartha-K61 Strain
2.3.2 HB98 Strain
2.3.3 C Strain
2.3.4 Other
2.3.5 Pseudorabies Virus Vaccine Sales by Strain Platform
2.3.5.1 Global Pseudorabies Virus Vaccine Sales Market Share by Strain Platform (2021-2026)
2.3.5.2 Global Pseudorabies Virus Vaccine Revenue and Market Share by Strain Platform (2021-2026)
2.3.5.3 Global Pseudorabies Virus Vaccine Sale Price by Strain Platform (2021-2026)
2.4 Pseudorabies Virus Vaccine Segment by Dose Pack Size
2.4.1 Small Pack (Below 20 Doses per Vial)
2.4.2 Medium Pack (20?50 Doses per Vial)
2.4.3 Large Pack (Above 50 Doses per Vial)
2.4.4 Pseudorabies Virus Vaccine Sales by Dose Pack Size
2.4.4.1 Global Pseudorabies Virus Vaccine Sales Market Share by Dose Pack Size (2021-2026)
2.4.4.2 Global Pseudorabies Virus Vaccine Revenue and Market Share by Dose Pack Size (2021-2026)
2.4.4.3 Global Pseudorabies Virus Vaccine Sale Price by Dose Pack Size (2021-2026)
2.5 Pseudorabies Virus Vaccine Segment by Application
2.5.1 Large-scale Swine Farming Groups
2.5.2 Breeding Farms
2.5.3 Animal Disease Control Institutions
2.5.4 Others
2.5.5 Pseudorabies Virus Vaccine Sales by Application
2.5.5.1 Global Pseudorabies Virus Vaccine Sale Market Share by Application (2021-2026)
2.5.5.2 Global Pseudorabies Virus Vaccine Revenue and Market Share by Application (2021-2026)
2.5.5.3 Global Pseudorabies Virus Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Pseudorabies Virus Vaccine Breakdown Data by Company
3.1.1 Global Pseudorabies Virus Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global Pseudorabies Virus Vaccine Sales Market Share by Company (2021-2026)
3.2 Global Pseudorabies Virus Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global Pseudorabies Virus Vaccine Revenue by Company (2021-2026)
3.2.2 Global Pseudorabies Virus Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global Pseudorabies Virus Vaccine Sale Price by Company
3.4 Key Manufacturers Pseudorabies Virus Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Pseudorabies Virus Vaccine Product Location Distribution
3.4.2 Players Pseudorabies Virus Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PSEUDORABIES VIRUS VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Pseudorabies Virus Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global Pseudorabies Virus Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Pseudorabies Virus Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Pseudorabies Virus Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global Pseudorabies Virus Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Pseudorabies Virus Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Pseudorabies Virus Vaccine Sales Growth
4.4 APAC Pseudorabies Virus Vaccine Sales Growth
4.5 Europe Pseudorabies Virus Vaccine Sales Growth
4.6 Middle East & Africa Pseudorabies Virus Vaccine Sales Growth
5 AMERICAS
5.1 Americas Pseudorabies Virus Vaccine Sales by Country
5.1.1 Americas Pseudorabies Virus Vaccine Sales by Country (2021-2026)
5.1.2 Americas Pseudorabies Virus Vaccine Revenue by Country (2021-2026)
5.2 Americas Pseudorabies Virus Vaccine Sales by Type (2021-2026)
5.3 Americas Pseudorabies Virus Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Pseudorabies Virus Vaccine Sales by Region
6.1.1 APAC Pseudorabies Virus Vaccine Sales by Region (2021-2026)
6.1.2 APAC Pseudorabies Virus Vaccine Revenue by Region (2021-2026)
6.2 APAC Pseudorabies Virus Vaccine Sales by Type (2021-2026)
6.3 APAC Pseudorabies Virus Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Pseudorabies Virus Vaccine by Country
7.1.1 Europe Pseudorabies Virus Vaccine Sales by Country (2021-2026)
7.1.2 Europe Pseudorabies Virus Vaccine Revenue by Country (2021-2026)
7.2 Europe Pseudorabies Virus Vaccine Sales by Type (2021-2026)
7.3 Europe Pseudorabies Virus Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Pseudorabies Virus Vaccine by Country
8.1.1 Middle East & Africa Pseudorabies Virus Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Pseudorabies Virus Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa Pseudorabies Virus Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa Pseudorabies Virus Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Pseudorabies Virus Vaccine
10.3 Manufacturing Process Analysis of Pseudorabies Virus Vaccine
10.4 Industry Chain Structure of Pseudorabies Virus Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Pseudorabies Virus Vaccine Distributors
11.3 Pseudorabies Virus Vaccine Customer
12 WORLD FORECAST REVIEW FOR PSEUDORABIES VIRUS VACCINE BY GEOGRAPHIC REGION
12.1 Global Pseudorabies Virus Vaccine Market Size Forecast by Region
12.1.1 Global Pseudorabies Virus Vaccine Forecast by Region (2027-2032)
12.1.2 Global Pseudorabies Virus Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Pseudorabies Virus Vaccine Forecast by Type (2027-2032)
12.7 Global Pseudorabies Virus Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 MSD Animal Health
13.1.1 MSD Animal Health Company Information
13.1.2 MSD Animal Health Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.1.3 MSD Animal Health Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 MSD Animal Health Main Business Overview
13.1.5 MSD Animal Health Latest Developments
13.2 Boehringer Ingelheim
13.2.1 Boehringer Ingelheim Company Information
13.2.2 Boehringer Ingelheim Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.2.3 Boehringer Ingelheim Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Boehringer Ingelheim Main Business Overview
13.2.5 Boehringer Ingelheim Latest Developments
13.3 HIPRA
13.3.1 HIPRA Company Information
13.3.2 HIPRA Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.3.3 HIPRA Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 HIPRA Main Business Overview
13.3.5 HIPRA Latest Developments
13.4 Ceva Sant? Animale
13.4.1 Ceva Sant? Animale Company Information
13.4.2 Ceva Sant? Animale Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.4.3 Ceva Sant? Animale Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Ceva Sant? Animale Main Business Overview
13.4.5 Ceva Sant? Animale Latest Developments
13.5 Wuhan Keqian Biology
13.5.1 Wuhan Keqian Biology Company Information
13.5.2 Wuhan Keqian Biology Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.5.3 Wuhan Keqian Biology Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Wuhan Keqian Biology Main Business Overview
13.5.5 Wuhan Keqian Biology Latest Developments
13.6 Pulike Biological Engineering
13.6.1 Pulike Biological Engineering Company Information
13.6.2 Pulike Biological Engineering Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.6.3 Pulike Biological Engineering Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Pulike Biological Engineering Main Business Overview
13.6.5 Pulike Biological Engineering Latest Developments
13.7 China Animal Husbandry Industry
13.7.1 China Animal Husbandry Industry Company Information
13.7.2 China Animal Husbandry Industry Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.7.3 China Animal Husbandry Industry Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 China Animal Husbandry Industry Main Business Overview
13.7.5 China Animal Husbandry Industry Latest Developments
13.8 Jinyu Bio-Technology
13.8.1 Jinyu Bio-Technology Company Information
13.8.2 Jinyu Bio-Technology Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.8.3 Jinyu Bio-Technology Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Jinyu Bio-Technology Main Business Overview
13.8.5 Jinyu Bio-Technology Latest Developments
13.9 Guangdong Winsun Bio-Pharmaceutical
13.9.1 Guangdong Winsun Bio-Pharmaceutical Company Information
13.9.2 Guangdong Winsun Bio-Pharmaceutical Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.9.3 Guangdong Winsun Bio-Pharmaceutical Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Guangdong Winsun Bio-Pharmaceutical Main Business Overview
13.9.5 Guangdong Winsun Bio-Pharmaceutical Latest Developments
13.10 Huapai Biopharm
13.10.1 Huapai Biopharm Company Information
13.10.2 Huapai Biopharm Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.10.3 Huapai Biopharm Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Huapai Biopharm Main Business Overview
13.10.5 Huapai Biopharm Latest Developments
13.11 Jilin Zhengye Biological Products
13.11.1 Jilin Zhengye Biological Products Company Information
13.11.2 Jilin Zhengye Biological Products Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.11.3 Jilin Zhengye Biological Products Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Jilin Zhengye Biological Products Main Business Overview
13.11.5 Jilin Zhengye Biological Products Latest Developments
13.12 Sinopharm Yangzhou VAC Biological Engineering
13.12.1 Sinopharm Yangzhou VAC Biological Engineering Company Information
13.12.2 Sinopharm Yangzhou VAC Biological Engineering Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.12.3 Sinopharm Yangzhou VAC Biological Engineering Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Sinopharm Yangzhou VAC Biological Engineering Main Business Overview
13.12.5 Sinopharm Yangzhou VAC Biological Engineering Latest Developments
13.13 Sinovet Animal Health
13.13.1 Sinovet Animal Health Company Information
13.13.2 Sinovet Animal Health Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.13.3 Sinovet Animal Health Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Sinovet Animal Health Main Business Overview
13.13.5 Sinovet Animal Health Latest Developments
13.14 Jofunhwa Group
13.14.1 Jofunhwa Group Company Information
13.14.2 Jofunhwa Group Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.14.3 Jofunhwa Group Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Jofunhwa Group Main Business Overview
13.14.5 Jofunhwa Group Latest Developments
13.15 Harbin Weike Biotechnology
13.15.1 Harbin Weike Biotechnology Company Information
13.15.2 Harbin Weike Biotechnology Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.15.3 Harbin Weike Biotechnology Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Harbin Weike Biotechnology Main Business Overview
13.15.5 Harbin Weike Biotechnology Latest Developments
13.16 Qilu Animal Health Products
13.16.1 Qilu Animal Health Products Company Information
13.16.2 Qilu Animal Health Products Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.16.3 Qilu Animal Health Products Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Qilu Animal Health Products Main Business Overview
13.16.5 Qilu Animal Health Products Latest Developments
13.17 Harbin Pharmaceutical Group Bio-vaccine
13.17.1 Harbin Pharmaceutical Group Bio-vaccine Company Information
13.17.2 Harbin Pharmaceutical Group Bio-vaccine Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.17.3 Harbin Pharmaceutical Group Bio-vaccine Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Harbin Pharmaceutical Group Bio-vaccine Main Business Overview
13.17.5 Harbin Pharmaceutical Group Bio-vaccine Latest Developments
13.18 Qingdao Yebio Bioengineering
13.18.1 Qingdao Yebio Bioengineering Company Information
13.18.2 Qingdao Yebio Bioengineering Pseudorabies Virus Vaccine Product Portfolios and Specifications
13.18.3 Qingdao Yebio Bioengineering Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Qingdao Yebio Bioengineering Main Business Overview
13.18.5 Qingdao Yebio Bioengineering Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Pseudorabies Virus Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Pseudorabies Virus Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Live Attenuated Vaccine
Table 4. Major Players of Inactivated Vaccine
Table 5. Major Players of Others
Table 6. Global Pseudorabies Virus Vaccine Sales by Type (2021-2026) & (K Dose)
Table 7. Global Pseudorabies Virus Vaccine Sales Market Share by Type (2021-2026)
Table 8. Global Pseudorabies Virus Vaccine Revenue by Type (2021-2026) & ($ million)
Table 9. Global Pseudorabies Virus Vaccine Revenue Market Share by Type (2021-2026)
Table 10. Global Pseudorabies Virus Vaccine Sale Price by Type (2021-2026) & (US$/Dose)
Table 11. Major Players of Bartha-K61 Strain
Table 12. Major Players of HB98 Strain
Table 13. Major Players of C Strain
Table 14. Major Players of Other
Table 15. Global Pseudorabies Virus Vaccine Sales by Strain Platform (2021-2026) & (K Dose)
Table 16. Global Pseudorabies Virus Vaccine Sales Market Share by Strain Platform (2021-2026)
Table 17. Global Pseudorabies Virus Vaccine Revenue by Strain Platform (2021-2026) & ($ million)
Table 18. Global Pseudorabies Virus Vaccine Revenue Market Share by Strain Platform (2021-2026)
Table 19. Global Pseudorabies Virus Vaccine Sale Price by Strain Platform (2021-2026) & (US$/Dose)
Table 20. Major Players of Small Pack (Below 20 Doses per Vial)
Table 21. Major Players of Medium Pack (20?50 Doses per Vial)
Table 22. Major Players of Large Pack (Above 50 Doses per Vial)
Table 23. Global Pseudorabies Virus Vaccine Sales by Dose Pack Size (2021-2026) & (K Dose)
Table 24. Global Pseudorabies Virus Vaccine Sales Market Share by Dose Pack Size (2021-2026)
Table 25. Global Pseudorabies Virus Vaccine Revenue by Dose Pack Size (2021-2026) & ($ million)
Table 26. Global Pseudorabies Virus Vaccine Revenue Market Share by Dose Pack Size (2021-2026)
Table 27. Global Pseudorabies Virus Vaccine Sale Price by Dose Pack Size (2021-2026) & (US$/Dose)
Table 28. Global Pseudorabies Virus Vaccine Sale by Application (2021-2026) & (K Dose)
Table 29. Global Pseudorabies Virus Vaccine Sale Market Share by Application (2021-2026)
Table 30. Global Pseudorabies Virus Vaccine Revenue by Application (2021-2026) & ($ million)
Table 31. Global Pseudorabies Virus Vaccine Revenue Market Share by Application (2021-2026)
Table 32. Global Pseudorabies Virus Vaccine Sale Price by Application (2021-2026) & (US$/Dose)
Table 33. Global Pseudorabies Virus Vaccine Sales by Company (2021-2026) & (K Dose)
Table 34. Global Pseudorabies Virus Vaccine Sales Market Share by Company (2021-2026)
Table 35. Global Pseudorabies Virus Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 36. Global Pseudorabies Virus Vaccine Revenue Market Share by Company (2021-2026)
Table 37. Global Pseudorabies Virus Vaccine Sale Price by Company (2021-2026) & (US$/Dose)
Table 38. Key Manufacturers Pseudorabies Virus Vaccine Producing Area Distribution and Sales Area
Table 39. Players Pseudorabies Virus Vaccine Products Offered
Table 40. Pseudorabies Virus Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 41. New Products and Potential Entrants
Table 42. Market M&A Activity & Strategy
Table 43. Global Pseudorabies Virus Vaccine Sales by Geographic Region (2021-2026) & (K Dose)
Table 44. Global Pseudorabies Virus Vaccine Sales Market Share Geographic Region (2021-2026)
Table 45. Global Pseudorabies Virus Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 46. Global Pseudorabies Virus Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 47. Global Pseudorabies Virus Vaccine Sales by Country/Region (2021-2026) & (K Dose)
Table 48. Global Pseudorabies Virus Vaccine Sales Market Share by Country/Region (2021-2026)
Table 49. Global Pseudorabies Virus Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 50. Global Pseudorabies Virus Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 51. Americas Pseudorabies Virus Vaccine Sales by Country (2021-2026) & (K Dose)
Table 52. Americas Pseudorabies Virus Vaccine Sales Market Share by Country (2021-2026)
Table 53. Americas Pseudorabies Virus Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 54. Americas Pseudorabies Virus Vaccine Sales by Type (2021-2026) & (K Dose)
Table 55. Americas Pseudorabies Virus Vaccine Sales by Application (2021-2026) & (K Dose)
Table 56. APAC Pseudorabies Virus Vaccine Sales by Region (2021-2026) & (K Dose)
Table 57. APAC Pseudorabies Virus Vaccine Sales Market Share by Region (2021-2026)
Table 58. APAC Pseudorabies Virus Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 59. APAC Pseudorabies Virus Vaccine Sales by Type (2021-2026) & (K Dose)
Table 60. APAC Pseudorabies Virus Vaccine Sales by Application (2021-2026) & (K Dose)
Table 61. Europe Pseudorabies Virus Vaccine Sales by Country (2021-2026) & (K Dose)
Table 62. Europe Pseudorabies Virus Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 63. Europe Pseudorabies Virus Vaccine Sales by Type (2021-2026) & (K Dose)
Table 64. Europe Pseudorabies Virus Vaccine Sales by Application (2021-2026) & (K Dose)
Table 65. Middle East & Africa Pseudorabies Virus Vaccine Sales by Country (2021-2026) & (K Dose)
Table 66. Middle East & Africa Pseudorabies Virus Vaccine Revenue Market Share by Country (2021-2026)
Table 67. Middle East & Africa Pseudorabies Virus Vaccine Sales by Type (2021-2026) & (K Dose)
Table 68. Middle East & Africa Pseudorabies Virus Vaccine Sales by Application (2021-2026) & (K Dose)
Table 69. Key Market Drivers & Growth Opportunities of Pseudorabies Virus Vaccine
Table 70. Key Market Challenges & Risks of Pseudorabies Virus Vaccine
Table 71. Key Industry Trends of Pseudorabies Virus Vaccine
Table 72. Pseudorabies Virus Vaccine Raw Material
Table 73. Key Suppliers of Raw Materials
Table 74. Pseudorabies Virus Vaccine Distributors List
Table 75. Pseudorabies Virus Vaccine Customer List
Table 76. Global Pseudorabies Virus Vaccine Sales Forecast by Region (2027-2032) & (K Dose)
Table 77. Global Pseudorabies Virus Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 78. Americas Pseudorabies Virus Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 79. Americas Pseudorabies Virus Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 80. APAC Pseudorabies Virus Vaccine Sales Forecast by Region (2027-2032) & (K Dose)
Table 81. APAC Pseudorabies Virus Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 82. Europe Pseudorabies Virus Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 83. Europe Pseudorabies Virus Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 84. Middle East & Africa Pseudorabies Virus Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 85. Middle East & Africa Pseudorabies Virus Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 86. Global Pseudorabies Virus Vaccine Sales Forecast by Type (2027-2032) & (K Dose)
Table 87. Global Pseudorabies Virus Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 88. Global Pseudorabies Virus Vaccine Sales Forecast by Application (2027-2032) & (K Dose)
Table 89. Global Pseudorabies Virus Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 90. MSD Animal Health Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 91. MSD Animal Health Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 92. MSD Animal Health Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 93. MSD Animal Health Main Business
Table 94. MSD Animal Health Latest Developments
Table 95. Boehringer Ingelheim Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 96. Boehringer Ingelheim Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 97. Boehringer Ingelheim Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 98. Boehringer Ingelheim Main Business
Table 99. Boehringer Ingelheim Latest Developments
Table 100. HIPRA Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 101. HIPRA Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 102. HIPRA Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 103. HIPRA Main Business
Table 104. HIPRA Latest Developments
Table 105. Ceva Sant? Animale Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 106. Ceva Sant? Animale Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 107. Ceva Sant? Animale Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 108. Ceva Sant? Animale Main Business
Table 109. Ceva Sant? Animale Latest Developments
Table 110. Wuhan Keqian Biology Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 111. Wuhan Keqian Biology Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 112. Wuhan Keqian Biology Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 113. Wuhan Keqian Biology Main Business
Table 114. Wuhan Keqian Biology Latest Developments
Table 115. Pulike Biological Engineering Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 116. Pulike Biological Engineering Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 117. Pulike Biological Engineering Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 118. Pulike Biological Engineering Main Business
Table 119. Pulike Biological Engineering Latest Developments
Table 120. China Animal Husbandry Industry Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 121. China Animal Husbandry Industry Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 122. China Animal Husbandry Industry Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 123. China Animal Husbandry Industry Main Business
Table 124. China Animal Husbandry Industry Latest Developments
Table 125. Jinyu Bio-Technology Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 126. Jinyu Bio-Technology Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 127. Jinyu Bio-Technology Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 128. Jinyu Bio-Technology Main Business
Table 129. Jinyu Bio-Technology Latest Developments
Table 130. Guangdong Winsun Bio-Pharmaceutical Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 131. Guangdong Winsun Bio-Pharmaceutical Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 132. Guangdong Winsun Bio-Pharmaceutical Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 133. Guangdong Winsun Bio-Pharmaceutical Main Business
Table 134. Guangdong Winsun Bio-Pharmaceutical Latest Developments
Table 135. Huapai Biopharm Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 136. Huapai Biopharm Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 137. Huapai Biopharm Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 138. Huapai Biopharm Main Business
Table 139. Huapai Biopharm Latest Developments
Table 140. Jilin Zhengye Biological Products Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 141. Jilin Zhengye Biological Products Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 142. Jilin Zhengye Biological Products Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 143. Jilin Zhengye Biological Products Main Business
Table 144. Jilin Zhengye Biological Products Latest Developments
Table 145. Sinopharm Yangzhou VAC Biological Engineering Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 146. Sinopharm Yangzhou VAC Biological Engineering Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 147. Sinopharm Yangzhou VAC Biological Engineering Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 148. Sinopharm Yangzhou VAC Biological Engineering Main Business
Table 149. Sinopharm Yangzhou VAC Biological Engineering Latest Developments
Table 150. Sinovet Animal Health Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 151. Sinovet Animal Health Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 152. Sinovet Animal Health Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 153. Sinovet Animal Health Main Business
Table 154. Sinovet Animal Health Latest Developments
Table 155. Jofunhwa Group Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 156. Jofunhwa Group Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 157. Jofunhwa Group Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 158. Jofunhwa Group Main Business
Table 159. Jofunhwa Group Latest Developments
Table 160. Harbin Weike Biotechnology Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 161. Harbin Weike Biotechnology Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 162. Harbin Weike Biotechnology Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 163. Harbin Weike Biotechnology Main Business
Table 164. Harbin Weike Biotechnology Latest Developments
Table 165. Qilu Animal Health Products Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 166. Qilu Animal Health Products Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 167. Qilu Animal Health Products Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 168. Qilu Animal Health Products Main Business
Table 169. Qilu Animal Health Products Latest Developments
Table 170. Harbin Pharmaceutical Group Bio-vaccine Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 171. Harbin Pharmaceutical Group Bio-vaccine Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 172. Harbin Pharmaceutical Group Bio-vaccine Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 173. Harbin Pharmaceutical Group Bio-vaccine Main Business
Table 174. Harbin Pharmaceutical Group Bio-vaccine Latest Developments
Table 175. Qingdao Yebio Bioengineering Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 176. Qingdao Yebio Bioengineering Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 177. Qingdao Yebio Bioengineering Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 178. Qingdao Yebio Bioengineering Main Business
Table 179. Qingdao Yebio Bioengineering Latest Developments
Table 1. Pseudorabies Virus Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Pseudorabies Virus Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Live Attenuated Vaccine
Table 4. Major Players of Inactivated Vaccine
Table 5. Major Players of Others
Table 6. Global Pseudorabies Virus Vaccine Sales by Type (2021-2026) & (K Dose)
Table 7. Global Pseudorabies Virus Vaccine Sales Market Share by Type (2021-2026)
Table 8. Global Pseudorabies Virus Vaccine Revenue by Type (2021-2026) & ($ million)
Table 9. Global Pseudorabies Virus Vaccine Revenue Market Share by Type (2021-2026)
Table 10. Global Pseudorabies Virus Vaccine Sale Price by Type (2021-2026) & (US$/Dose)
Table 11. Major Players of Bartha-K61 Strain
Table 12. Major Players of HB98 Strain
Table 13. Major Players of C Strain
Table 14. Major Players of Other
Table 15. Global Pseudorabies Virus Vaccine Sales by Strain Platform (2021-2026) & (K Dose)
Table 16. Global Pseudorabies Virus Vaccine Sales Market Share by Strain Platform (2021-2026)
Table 17. Global Pseudorabies Virus Vaccine Revenue by Strain Platform (2021-2026) & ($ million)
Table 18. Global Pseudorabies Virus Vaccine Revenue Market Share by Strain Platform (2021-2026)
Table 19. Global Pseudorabies Virus Vaccine Sale Price by Strain Platform (2021-2026) & (US$/Dose)
Table 20. Major Players of Small Pack (Below 20 Doses per Vial)
Table 21. Major Players of Medium Pack (20?50 Doses per Vial)
Table 22. Major Players of Large Pack (Above 50 Doses per Vial)
Table 23. Global Pseudorabies Virus Vaccine Sales by Dose Pack Size (2021-2026) & (K Dose)
Table 24. Global Pseudorabies Virus Vaccine Sales Market Share by Dose Pack Size (2021-2026)
Table 25. Global Pseudorabies Virus Vaccine Revenue by Dose Pack Size (2021-2026) & ($ million)
Table 26. Global Pseudorabies Virus Vaccine Revenue Market Share by Dose Pack Size (2021-2026)
Table 27. Global Pseudorabies Virus Vaccine Sale Price by Dose Pack Size (2021-2026) & (US$/Dose)
Table 28. Global Pseudorabies Virus Vaccine Sale by Application (2021-2026) & (K Dose)
Table 29. Global Pseudorabies Virus Vaccine Sale Market Share by Application (2021-2026)
Table 30. Global Pseudorabies Virus Vaccine Revenue by Application (2021-2026) & ($ million)
Table 31. Global Pseudorabies Virus Vaccine Revenue Market Share by Application (2021-2026)
Table 32. Global Pseudorabies Virus Vaccine Sale Price by Application (2021-2026) & (US$/Dose)
Table 33. Global Pseudorabies Virus Vaccine Sales by Company (2021-2026) & (K Dose)
Table 34. Global Pseudorabies Virus Vaccine Sales Market Share by Company (2021-2026)
Table 35. Global Pseudorabies Virus Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 36. Global Pseudorabies Virus Vaccine Revenue Market Share by Company (2021-2026)
Table 37. Global Pseudorabies Virus Vaccine Sale Price by Company (2021-2026) & (US$/Dose)
Table 38. Key Manufacturers Pseudorabies Virus Vaccine Producing Area Distribution and Sales Area
Table 39. Players Pseudorabies Virus Vaccine Products Offered
Table 40. Pseudorabies Virus Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 41. New Products and Potential Entrants
Table 42. Market M&A Activity & Strategy
Table 43. Global Pseudorabies Virus Vaccine Sales by Geographic Region (2021-2026) & (K Dose)
Table 44. Global Pseudorabies Virus Vaccine Sales Market Share Geographic Region (2021-2026)
Table 45. Global Pseudorabies Virus Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 46. Global Pseudorabies Virus Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 47. Global Pseudorabies Virus Vaccine Sales by Country/Region (2021-2026) & (K Dose)
Table 48. Global Pseudorabies Virus Vaccine Sales Market Share by Country/Region (2021-2026)
Table 49. Global Pseudorabies Virus Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 50. Global Pseudorabies Virus Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 51. Americas Pseudorabies Virus Vaccine Sales by Country (2021-2026) & (K Dose)
Table 52. Americas Pseudorabies Virus Vaccine Sales Market Share by Country (2021-2026)
Table 53. Americas Pseudorabies Virus Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 54. Americas Pseudorabies Virus Vaccine Sales by Type (2021-2026) & (K Dose)
Table 55. Americas Pseudorabies Virus Vaccine Sales by Application (2021-2026) & (K Dose)
Table 56. APAC Pseudorabies Virus Vaccine Sales by Region (2021-2026) & (K Dose)
Table 57. APAC Pseudorabies Virus Vaccine Sales Market Share by Region (2021-2026)
Table 58. APAC Pseudorabies Virus Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 59. APAC Pseudorabies Virus Vaccine Sales by Type (2021-2026) & (K Dose)
Table 60. APAC Pseudorabies Virus Vaccine Sales by Application (2021-2026) & (K Dose)
Table 61. Europe Pseudorabies Virus Vaccine Sales by Country (2021-2026) & (K Dose)
Table 62. Europe Pseudorabies Virus Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 63. Europe Pseudorabies Virus Vaccine Sales by Type (2021-2026) & (K Dose)
Table 64. Europe Pseudorabies Virus Vaccine Sales by Application (2021-2026) & (K Dose)
Table 65. Middle East & Africa Pseudorabies Virus Vaccine Sales by Country (2021-2026) & (K Dose)
Table 66. Middle East & Africa Pseudorabies Virus Vaccine Revenue Market Share by Country (2021-2026)
Table 67. Middle East & Africa Pseudorabies Virus Vaccine Sales by Type (2021-2026) & (K Dose)
Table 68. Middle East & Africa Pseudorabies Virus Vaccine Sales by Application (2021-2026) & (K Dose)
Table 69. Key Market Drivers & Growth Opportunities of Pseudorabies Virus Vaccine
Table 70. Key Market Challenges & Risks of Pseudorabies Virus Vaccine
Table 71. Key Industry Trends of Pseudorabies Virus Vaccine
Table 72. Pseudorabies Virus Vaccine Raw Material
Table 73. Key Suppliers of Raw Materials
Table 74. Pseudorabies Virus Vaccine Distributors List
Table 75. Pseudorabies Virus Vaccine Customer List
Table 76. Global Pseudorabies Virus Vaccine Sales Forecast by Region (2027-2032) & (K Dose)
Table 77. Global Pseudorabies Virus Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 78. Americas Pseudorabies Virus Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 79. Americas Pseudorabies Virus Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 80. APAC Pseudorabies Virus Vaccine Sales Forecast by Region (2027-2032) & (K Dose)
Table 81. APAC Pseudorabies Virus Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 82. Europe Pseudorabies Virus Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 83. Europe Pseudorabies Virus Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 84. Middle East & Africa Pseudorabies Virus Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 85. Middle East & Africa Pseudorabies Virus Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 86. Global Pseudorabies Virus Vaccine Sales Forecast by Type (2027-2032) & (K Dose)
Table 87. Global Pseudorabies Virus Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 88. Global Pseudorabies Virus Vaccine Sales Forecast by Application (2027-2032) & (K Dose)
Table 89. Global Pseudorabies Virus Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 90. MSD Animal Health Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 91. MSD Animal Health Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 92. MSD Animal Health Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 93. MSD Animal Health Main Business
Table 94. MSD Animal Health Latest Developments
Table 95. Boehringer Ingelheim Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 96. Boehringer Ingelheim Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 97. Boehringer Ingelheim Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 98. Boehringer Ingelheim Main Business
Table 99. Boehringer Ingelheim Latest Developments
Table 100. HIPRA Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 101. HIPRA Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 102. HIPRA Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 103. HIPRA Main Business
Table 104. HIPRA Latest Developments
Table 105. Ceva Sant? Animale Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 106. Ceva Sant? Animale Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 107. Ceva Sant? Animale Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 108. Ceva Sant? Animale Main Business
Table 109. Ceva Sant? Animale Latest Developments
Table 110. Wuhan Keqian Biology Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 111. Wuhan Keqian Biology Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 112. Wuhan Keqian Biology Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 113. Wuhan Keqian Biology Main Business
Table 114. Wuhan Keqian Biology Latest Developments
Table 115. Pulike Biological Engineering Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 116. Pulike Biological Engineering Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 117. Pulike Biological Engineering Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 118. Pulike Biological Engineering Main Business
Table 119. Pulike Biological Engineering Latest Developments
Table 120. China Animal Husbandry Industry Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 121. China Animal Husbandry Industry Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 122. China Animal Husbandry Industry Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 123. China Animal Husbandry Industry Main Business
Table 124. China Animal Husbandry Industry Latest Developments
Table 125. Jinyu Bio-Technology Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 126. Jinyu Bio-Technology Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 127. Jinyu Bio-Technology Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 128. Jinyu Bio-Technology Main Business
Table 129. Jinyu Bio-Technology Latest Developments
Table 130. Guangdong Winsun Bio-Pharmaceutical Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 131. Guangdong Winsun Bio-Pharmaceutical Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 132. Guangdong Winsun Bio-Pharmaceutical Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 133. Guangdong Winsun Bio-Pharmaceutical Main Business
Table 134. Guangdong Winsun Bio-Pharmaceutical Latest Developments
Table 135. Huapai Biopharm Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 136. Huapai Biopharm Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 137. Huapai Biopharm Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 138. Huapai Biopharm Main Business
Table 139. Huapai Biopharm Latest Developments
Table 140. Jilin Zhengye Biological Products Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 141. Jilin Zhengye Biological Products Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 142. Jilin Zhengye Biological Products Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 143. Jilin Zhengye Biological Products Main Business
Table 144. Jilin Zhengye Biological Products Latest Developments
Table 145. Sinopharm Yangzhou VAC Biological Engineering Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 146. Sinopharm Yangzhou VAC Biological Engineering Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 147. Sinopharm Yangzhou VAC Biological Engineering Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 148. Sinopharm Yangzhou VAC Biological Engineering Main Business
Table 149. Sinopharm Yangzhou VAC Biological Engineering Latest Developments
Table 150. Sinovet Animal Health Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 151. Sinovet Animal Health Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 152. Sinovet Animal Health Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 153. Sinovet Animal Health Main Business
Table 154. Sinovet Animal Health Latest Developments
Table 155. Jofunhwa Group Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 156. Jofunhwa Group Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 157. Jofunhwa Group Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 158. Jofunhwa Group Main Business
Table 159. Jofunhwa Group Latest Developments
Table 160. Harbin Weike Biotechnology Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 161. Harbin Weike Biotechnology Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 162. Harbin Weike Biotechnology Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 163. Harbin Weike Biotechnology Main Business
Table 164. Harbin Weike Biotechnology Latest Developments
Table 165. Qilu Animal Health Products Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 166. Qilu Animal Health Products Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 167. Qilu Animal Health Products Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 168. Qilu Animal Health Products Main Business
Table 169. Qilu Animal Health Products Latest Developments
Table 170. Harbin Pharmaceutical Group Bio-vaccine Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 171. Harbin Pharmaceutical Group Bio-vaccine Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 172. Harbin Pharmaceutical Group Bio-vaccine Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 173. Harbin Pharmaceutical Group Bio-vaccine Main Business
Table 174. Harbin Pharmaceutical Group Bio-vaccine Latest Developments
Table 175. Qingdao Yebio Bioengineering Basic Information, Pseudorabies Virus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 176. Qingdao Yebio Bioengineering Pseudorabies Virus Vaccine Product Portfolios and Specifications
Table 177. Qingdao Yebio Bioengineering Pseudorabies Virus Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 178. Qingdao Yebio Bioengineering Main Business
Table 179. Qingdao Yebio Bioengineering Latest Developments
LIST OF FIGURES
Figure 1. Picture of Pseudorabies Virus Vaccine
Figure 2. Pseudorabies Virus Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Pseudorabies Virus Vaccine Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global Pseudorabies Virus Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Pseudorabies Virus Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Pseudorabies Virus Vaccine Sales Market Share by Country/Region (2025)
Figure 10. Pseudorabies Virus Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Live Attenuated Vaccine
Figure 12. Product Picture of Inactivated Vaccine
Figure 13. Product Picture of Others
Figure 14. Global Pseudorabies Virus Vaccine Sales Market Share by Type in 2026
Figure 15. Global Pseudorabies Virus Vaccine Revenue Market Share by Type (2021-2026)
Figure 16. Product Picture of Bartha-K61 Strain
Figure 17. Product Picture of HB98 Strain
Figure 18. Product Picture of C Strain
Figure 19. Product Picture of Other
Figure 20. Global Pseudorabies Virus Vaccine Sales Market Share by Strain Platform in 2026
Figure 21. Global Pseudorabies Virus Vaccine Revenue Market Share by Strain Platform (2021-2026)
Figure 22. Product Picture of Small Pack (Below 20 Doses per Vial)
Figure 23. Product Picture of Medium Pack (20?50 Doses per Vial)
Figure 24. Product Picture of Large Pack (Above 50 Doses per Vial)
Figure 25. Global Pseudorabies Virus Vaccine Sales Market Share by Dose Pack Size in 2026
Figure 26. Global Pseudorabies Virus Vaccine Revenue Market Share by Dose Pack Size (2021-2026)
Figure 27. Pseudorabies Virus Vaccine Consumed in Large-scale Swine Farming Groups
Figure 28. Global Pseudorabies Virus Vaccine Market: Large-scale Swine Farming Groups (2021-2026) & (K Dose)
Figure 29. Pseudorabies Virus Vaccine Consumed in Breeding Farms
Figure 30. Global Pseudorabies Virus Vaccine Market: Breeding Farms (2021-2026) & (K Dose)
Figure 31. Pseudorabies Virus Vaccine Consumed in Animal Disease Control Institutions
Figure 32. Global Pseudorabies Virus Vaccine Market: Animal Disease Control Institutions (2021-2026) & (K Dose)
Figure 33. Pseudorabies Virus Vaccine Consumed in Others
Figure 34. Global Pseudorabies Virus Vaccine Market: Others (2021-2026) & (K Dose)
Figure 35. Global Pseudorabies Virus Vaccine Sale Market Share by Application (2025)
Figure 36. Global Pseudorabies Virus Vaccine Revenue Market Share by Application in 2025
Figure 37. Pseudorabies Virus Vaccine Sales by Company in 2025 (K Dose)
Figure 38. Global Pseudorabies Virus Vaccine Sales Market Share by Company in 2025
Figure 39. Pseudorabies Virus Vaccine Revenue by Company in 2025 ($ millions)
Figure 40. Global Pseudorabies Virus Vaccine Revenue Market Share by Company in 2025
Figure 41. Global Pseudorabies Virus Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 42. Global Pseudorabies Virus Vaccine Revenue Market Share by Geographic Region in 2025
Figure 43. Americas Pseudorabies Virus Vaccine Sales 2021-2026 (K Dose)
Figure 44. Americas Pseudorabies Virus Vaccine Revenue 2021-2026 ($ millions)
Figure 45. APAC Pseudorabies Virus Vaccine Sales 2021-2026 (K Dose)
Figure 46. APAC Pseudorabies Virus Vaccine Revenue 2021-2026 ($ millions)
Figure 47. Europe Pseudorabies Virus Vaccine Sales 2021-2026 (K Dose)
Figure 48. Europe Pseudorabies Virus Vaccine Revenue 2021-2026 ($ millions)
Figure 49. Middle East & Africa Pseudorabies Virus Vaccine Sales 2021-2026 (K Dose)
Figure 50. Middle East & Africa Pseudorabies Virus Vaccine Revenue 2021-2026 ($ millions)
Figure 51. Americas Pseudorabies Virus Vaccine Sales Market Share by Country in 2025
Figure 52. Americas Pseudorabies Virus Vaccine Revenue Market Share by Country (2021-2026)
Figure 53. Americas Pseudorabies Virus Vaccine Sales Market Share by Type (2021-2026)
Figure 54. Americas Pseudorabies Virus Vaccine Sales Market Share by Application (2021-2026)
Figure 55. United States Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 56. Canada Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 57. Mexico Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 58. Brazil Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 59. APAC Pseudorabies Virus Vaccine Sales Market Share by Region in 2025
Figure 60. APAC Pseudorabies Virus Vaccine Revenue Market Share by Region (2021-2026)
Figure 61. APAC Pseudorabies Virus Vaccine Sales Market Share by Type (2021-2026)
Figure 62. APAC Pseudorabies Virus Vaccine Sales Market Share by Application (2021-2026)
Figure 63. China Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 64. Japan Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 65. South Korea Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 66. Southeast Asia Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 67. India Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 68. Australia Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 69. China Taiwan Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 70. Europe Pseudorabies Virus Vaccine Sales Market Share by Country in 2025
Figure 71. Europe Pseudorabies Virus Vaccine Revenue Market Share by Country (2021-2026)
Figure 72. Europe Pseudorabies Virus Vaccine Sales Market Share by Type (2021-2026)
Figure 73. Europe Pseudorabies Virus Vaccine Sales Market Share by Application (2021-2026)
Figure 74. Germany Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 75. France Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 76. UK Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 77. Italy Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 78. Russia Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 79. Middle East & Africa Pseudorabies Virus Vaccine Sales Market Share by Country (2021-2026)
Figure 80. Middle East & Africa Pseudorabies Virus Vaccine Sales Market Share by Type (2021-2026)
Figure 81. Middle East & Africa Pseudorabies Virus Vaccine Sales Market Share by Application (2021-2026)
Figure 82. Egypt Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 83. South Africa Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 84. Israel Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 85. Turkey Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 86. GCC Countries Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 87. Manufacturing Cost Structure Analysis of Pseudorabies Virus Vaccine in 2026
Figure 88. Manufacturing Process Analysis of Pseudorabies Virus Vaccine
Figure 89. Industry Chain Structure of Pseudorabies Virus Vaccine
Figure 90. Channels of Distribution
Figure 91. Global Pseudorabies Virus Vaccine Sales Market Forecast by Region (2027-2032)
Figure 92. Global Pseudorabies Virus Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 93. Global Pseudorabies Virus Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 94. Global Pseudorabies Virus Vaccine Revenue Market Share Forecast by Type (2027-2032)
Figure 95. Global Pseudorabies Virus Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 96. Global Pseudorabies Virus Vaccine Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Pseudorabies Virus Vaccine
Figure 2. Pseudorabies Virus Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Pseudorabies Virus Vaccine Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global Pseudorabies Virus Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Pseudorabies Virus Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Pseudorabies Virus Vaccine Sales Market Share by Country/Region (2025)
Figure 10. Pseudorabies Virus Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Live Attenuated Vaccine
Figure 12. Product Picture of Inactivated Vaccine
Figure 13. Product Picture of Others
Figure 14. Global Pseudorabies Virus Vaccine Sales Market Share by Type in 2026
Figure 15. Global Pseudorabies Virus Vaccine Revenue Market Share by Type (2021-2026)
Figure 16. Product Picture of Bartha-K61 Strain
Figure 17. Product Picture of HB98 Strain
Figure 18. Product Picture of C Strain
Figure 19. Product Picture of Other
Figure 20. Global Pseudorabies Virus Vaccine Sales Market Share by Strain Platform in 2026
Figure 21. Global Pseudorabies Virus Vaccine Revenue Market Share by Strain Platform (2021-2026)
Figure 22. Product Picture of Small Pack (Below 20 Doses per Vial)
Figure 23. Product Picture of Medium Pack (20?50 Doses per Vial)
Figure 24. Product Picture of Large Pack (Above 50 Doses per Vial)
Figure 25. Global Pseudorabies Virus Vaccine Sales Market Share by Dose Pack Size in 2026
Figure 26. Global Pseudorabies Virus Vaccine Revenue Market Share by Dose Pack Size (2021-2026)
Figure 27. Pseudorabies Virus Vaccine Consumed in Large-scale Swine Farming Groups
Figure 28. Global Pseudorabies Virus Vaccine Market: Large-scale Swine Farming Groups (2021-2026) & (K Dose)
Figure 29. Pseudorabies Virus Vaccine Consumed in Breeding Farms
Figure 30. Global Pseudorabies Virus Vaccine Market: Breeding Farms (2021-2026) & (K Dose)
Figure 31. Pseudorabies Virus Vaccine Consumed in Animal Disease Control Institutions
Figure 32. Global Pseudorabies Virus Vaccine Market: Animal Disease Control Institutions (2021-2026) & (K Dose)
Figure 33. Pseudorabies Virus Vaccine Consumed in Others
Figure 34. Global Pseudorabies Virus Vaccine Market: Others (2021-2026) & (K Dose)
Figure 35. Global Pseudorabies Virus Vaccine Sale Market Share by Application (2025)
Figure 36. Global Pseudorabies Virus Vaccine Revenue Market Share by Application in 2025
Figure 37. Pseudorabies Virus Vaccine Sales by Company in 2025 (K Dose)
Figure 38. Global Pseudorabies Virus Vaccine Sales Market Share by Company in 2025
Figure 39. Pseudorabies Virus Vaccine Revenue by Company in 2025 ($ millions)
Figure 40. Global Pseudorabies Virus Vaccine Revenue Market Share by Company in 2025
Figure 41. Global Pseudorabies Virus Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 42. Global Pseudorabies Virus Vaccine Revenue Market Share by Geographic Region in 2025
Figure 43. Americas Pseudorabies Virus Vaccine Sales 2021-2026 (K Dose)
Figure 44. Americas Pseudorabies Virus Vaccine Revenue 2021-2026 ($ millions)
Figure 45. APAC Pseudorabies Virus Vaccine Sales 2021-2026 (K Dose)
Figure 46. APAC Pseudorabies Virus Vaccine Revenue 2021-2026 ($ millions)
Figure 47. Europe Pseudorabies Virus Vaccine Sales 2021-2026 (K Dose)
Figure 48. Europe Pseudorabies Virus Vaccine Revenue 2021-2026 ($ millions)
Figure 49. Middle East & Africa Pseudorabies Virus Vaccine Sales 2021-2026 (K Dose)
Figure 50. Middle East & Africa Pseudorabies Virus Vaccine Revenue 2021-2026 ($ millions)
Figure 51. Americas Pseudorabies Virus Vaccine Sales Market Share by Country in 2025
Figure 52. Americas Pseudorabies Virus Vaccine Revenue Market Share by Country (2021-2026)
Figure 53. Americas Pseudorabies Virus Vaccine Sales Market Share by Type (2021-2026)
Figure 54. Americas Pseudorabies Virus Vaccine Sales Market Share by Application (2021-2026)
Figure 55. United States Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 56. Canada Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 57. Mexico Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 58. Brazil Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 59. APAC Pseudorabies Virus Vaccine Sales Market Share by Region in 2025
Figure 60. APAC Pseudorabies Virus Vaccine Revenue Market Share by Region (2021-2026)
Figure 61. APAC Pseudorabies Virus Vaccine Sales Market Share by Type (2021-2026)
Figure 62. APAC Pseudorabies Virus Vaccine Sales Market Share by Application (2021-2026)
Figure 63. China Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 64. Japan Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 65. South Korea Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 66. Southeast Asia Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 67. India Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 68. Australia Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 69. China Taiwan Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 70. Europe Pseudorabies Virus Vaccine Sales Market Share by Country in 2025
Figure 71. Europe Pseudorabies Virus Vaccine Revenue Market Share by Country (2021-2026)
Figure 72. Europe Pseudorabies Virus Vaccine Sales Market Share by Type (2021-2026)
Figure 73. Europe Pseudorabies Virus Vaccine Sales Market Share by Application (2021-2026)
Figure 74. Germany Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 75. France Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 76. UK Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 77. Italy Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 78. Russia Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 79. Middle East & Africa Pseudorabies Virus Vaccine Sales Market Share by Country (2021-2026)
Figure 80. Middle East & Africa Pseudorabies Virus Vaccine Sales Market Share by Type (2021-2026)
Figure 81. Middle East & Africa Pseudorabies Virus Vaccine Sales Market Share by Application (2021-2026)
Figure 82. Egypt Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 83. South Africa Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 84. Israel Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 85. Turkey Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 86. GCC Countries Pseudorabies Virus Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 87. Manufacturing Cost Structure Analysis of Pseudorabies Virus Vaccine in 2026
Figure 88. Manufacturing Process Analysis of Pseudorabies Virus Vaccine
Figure 89. Industry Chain Structure of Pseudorabies Virus Vaccine
Figure 90. Channels of Distribution
Figure 91. Global Pseudorabies Virus Vaccine Sales Market Forecast by Region (2027-2032)
Figure 92. Global Pseudorabies Virus Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 93. Global Pseudorabies Virus Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 94. Global Pseudorabies Virus Vaccine Revenue Market Share Forecast by Type (2027-2032)
Figure 95. Global Pseudorabies Virus Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 96. Global Pseudorabies Virus Vaccine Revenue Market Share Forecast by Application (2027-2032)
